Clinical factors such as severity of infection on presentation and underlying comorbidities were the main factors influencing treatment decisions.
Dalbavancin is an effective and well-tolerated treatment for ABSSSI, including in patients who met SIRS criteria.
Compared with vancomycin, patients with ABSSSI treated with ceftaroline fosamil had significantly shorter length of hospital stay.
Omadacycline was non-inferior to moxifloxacin for treatment of CABP and linezolid for treatment of ABSSSI.
The goal of this post-hoc analysis of OASIS-1 study was to determine if BMI or T2D had any effect on the efficacy or safety of omadacycline relative to linezolid.
Although intramuscular antibiotics had been suggested as a prevention strategy for recurrent cellulitis, the evidence is scarce.
Researchers evaluated risk factors associated with secondary bloodstream infections in patients with acute bacterial skin and skin structure infections.
Dalbavancin has shown potent activity against gram-positive pathogens responsible for ABSSSI, including MRSA.
Study suggests a higher incidence of Fournier's gangrene than previously described.
Dalbavancin and oritavancin may make it possible to allow for earlier discharge and reduce health care costs without compromising efficacy.
Sign Up for Free e-newsletters
Check out what's trending
Infectious Disease Advisor Articles
- Novel H pylori Eradication Therapy Effective in Phase 3 Trial
- Polymyxin B Hemoperfusion Does Not Change Mortality Rate in Septic Shock
- New Four Drug Regimen Effective in Patients With HCV Who Inject Drugs
- Pediatric ART Leads to Increasing Mitochondrial DNA Mutations
- Prior Influenza Vaccination Not Associated With Future Vaccine Efficacy in Children